Table 1 Patient and tumor characteristics
Variable | Value | P value |
|---|---|---|
Age (year), median (range) | 47.35 ± 3.97 (40–55) | ≥ 0.05 |
Smoking, n (%) |  | ≥ 0.05 |
 Yes | 7(5%) |  |
 No | 135(95%) |  |
BMI, median (range) | 25.03 ± 2.1(20–32) | ≥ 0.05 |
Follow-up (months), median (range) | 16.5 ± 3.73(12–24) | ≥ 0.05 |
Menopausal status, n (%) |  | ≥ 0.05 |
Premenopausal | 47(33%) | Â |
Post-menopausal | 95(67%) | Â |
Stage of disease, n (%) |  | ≤ 0.05 |
 IIB | 19(13%) |  |
 IIIA | 31(22%) |  |
 IIIB | 39(28%) |  |
 IIIC | 53(37%) |  |
Tumor classification, n (%) |  | ≤ 0.001 |
 T1 | 0 |  |
 T2 | 0 |  |
 T3 | 36(25%) |  |
 T4 | 106(75%) |  |
Lymph node status, n (%) |  | ≤ 0.05 |
 N0 | 0 |  |
 N1 | 48(34%) |  |
 N2/N3 | 94(66%) |  |
ER, PR status at initial diagnosis, n (%) |  | ≥ 0.05 |
 Positive | 90(63.4%) |  |
 Negative | 52(33.6%) |  |
HER-2 status at initial diagnosis |  | ≥ 0.05 |
 Positive | 41(28.9%) |  |
 Negative | 101(71.1%) |  |
Surgical margin status, n (%) |  | ≥ 0.05 |
 Positive | 2(1%) |  |
 Negative | 140(99%) |  |
Skin invasion and ulceration, n (%) | Â | Â |
 Yes | 106(75%) |  |
 No | 36(25%) |  |
Pectoralis major | Â | Â |
 Yes | 53(37%) |  |
 No | 89(63%) |  |
Histological type, n (%) | Â | Â |
Infiltrating ductal carcinoma | 138(97%) | Â |
Inflammatory | 4(3%) | Â |
Molecular subtyping, n (%) |  | ≤ 0.05 |
 Luminal A | 38(26.8%) |  |
 Luminal B | 52(36.6%) |  |
Triplenegative | 31(21.8%) | Â |
HER-2 overexpression | 21(14.8%) | Â |